Group 1 - Guangdong Construction signed an EPC contract worth 416 million yuan, with a total construction area of 99,595.6 square meters and a construction period of 640 calendar days [1] - Hekang New Energy's subsidiary received a government subsidy of 6 million yuan, accounting for 58.27% of the company's latest audited net profit attributable to shareholders [2] - Jinbei Automotive signed a memorandum of understanding with E-Works to establish a research and development center for electric light commercial vehicles [3] Group 2 - Hongsheng Huayuan is expected to win approximately 569 million yuan in procurement projects from the State Grid, which represents about 5.61% of the company's projected revenue for 2024 [4] - Zhongding Co. plans to establish a joint venture for humanoid robot manufacturing with a registered capital of 50 million yuan [5] - Kede CNC's new factory in Shenyang is expected to achieve an annual production capacity of about 60 units [6] Group 3 - Hongbo Pharmaceutical's share transfer price is set at 25.27 yuan per share [7] - ST Jinglan plans to sign a letter of intent for the acquisition of Xinlian Environmental Technology Co., enhancing its core technology competitiveness [8][9] - Hato Co. announced the resignation of its general manager due to job relocation [10] Group 4 - Meibang Co. plans to apply for a new bank credit line of up to 160 million yuan [11] - Southern Media's general manager resigned due to job relocation [12] - Dalian Electric Porcelain's subsidiary is expected to win procurement projects from the State Grid worth approximately 70.7 million yuan [13] Group 5 - Sinopharm Modern's subsidiary received a drug registration certificate for a new medication [14] - ST Meigu plans to implement a capital reserve transfer to increase share capital, leading to a one-day stock suspension [15] - Ruisheng Intelligent confirmed a transaction of 152 million yuan for domestic computing equipment procurement [16] Group 6 - Jinguang Electric won three procurement packages from the State Grid, totaling 37.43 million yuan [17] - Guangju Energy increased its stake in Mawan Power to 14.42% by acquiring an 8% share for 680 million yuan [18][19] - ST Lingda announced a stock suspension due to capital reserve transfer related to its restructuring plan [20] Group 7 - Suli Co. plans to increase its investment in Suli Ningxia by 76.63 million yuan [21] - Dalian Shengya's subsidiary plans to reduce its registered capital by 32.37 million yuan [22] - Yinxin Technology received a cash dividend of 11.05 million yuan from its subsidiary [23] Group 8 - Haike New Source signed a three-year supply agreement for 270,000 tons of electrolyte materials [24] - Xinhua Medical received registration certificates for several medical devices [25] - Wantai Bio received a registration certificate for an HIV antibody testing kit [26] Group 9 - Beilu Pharmaceutical obtained a drug registration certificate for a new erectile dysfunction treatment [31] - Zhongwei Company is planning to issue shares to acquire assets, leading to a stock suspension [32] - Zhejiang Haideman plans to purchase land for strategic development, with a budget of up to 260 million yuan [33] Group 10 - Ningbo Ocean announced the resignation of its deputy general manager due to job adjustments [34] - Tongguang Cable is expected to win procurement projects from the State Grid worth over 139 million yuan [35]

Core Viewpoint - Beilu Pharmaceutical has received approval from the National Medical Products Administration for the registration of sildenafil citrate orally disintegrating tablets, which are designed to treat erectile dysfunction and offer rapid onset and effective results [1] Group 1: Product Details - Sildenafil is a selective inhibitor of phosphodiesterase type 5, used for treating erectile dysfunction, and is known for its rapid action and efficacy [1] - The orally disintegrating tablet form of sildenafil citrate was developed by Pfizer and was approved for import into China in 2019 [1] - This formulation does not require water for consumption, dissolves in the mouth within seconds, and provides a quick onset of action, catering to patients' needs for convenience, rapid effect, and privacy in medication [1]

Core Viewpoint - Beilu Pharmaceutical has received approval from the National Medical Products Administration for the registration certificate of Sildenafil Citrate Orally Disintegrating Tablets, which is a significant development for the company in the erectile dysfunction treatment market [1] Company Summary - Beilu Pharmaceutical (300016.SZ) has announced the receipt of a drug registration certificate for Sildenafil Citrate Orally Disintegrating Tablets from the National Medical Products Administration [1] - Sildenafil is a selective phosphodiesterase type 5 inhibitor used for treating erectile dysfunction, known for its rapid onset and effective results [1] - The orally disintegrating tablet form of Sildenafil, developed by Pfizer, was approved for import in China in 2019, indicating a strategic move to enhance product offerings in the market [1] Industry Summary - The Sildenafil Citrate Orally Disintegrating Tablets provide a convenient and discreet option for patients, as they dissolve in the mouth without the need for water and have a quick onset of action [1] - This product addresses the growing demand for flexible and diverse oral medication options among patients suffering from erectile dysfunction [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Sildenafil Citrate Orally Disintegrating Tablets, which is a selective phosphodiesterase type 5 inhibitor used for treating erectile dysfunction [1] Group 1: Product Details - Sildenafil Citrate is known for its rapid onset of action and effective treatment for erectile dysfunction [1] - The orally disintegrating tablet formulation allows for administration without water, dissolving in the mouth within seconds, thus providing a convenient and discreet option for patients [1] - This formulation meets the demand for convenient, fast-acting, and privacy-preserving oral medications among patients [1] Group 2: Market Context - The orally disintegrating tablet is an iteration of the original Sildenafil developed by Pfizer, which was approved for import in China in 2019 [1]

Core Viewpoint - Beilu Pharmaceutical (300016.SZ) has received the drug registration certificate for Sildenafil Citrate Orally Disintegrating Tablets from the National Medical Products Administration, indicating a significant advancement in its product portfolio [1] Company Summary - Beilu Pharmaceutical has announced the approval of Sildenafil Citrate Orally Disintegrating Tablets, a formulation designed for the treatment of erectile dysfunction [1] - The orally disintegrating form of sildenafil offers advantages such as rapid onset of action and confirmed efficacy, catering to patient needs for convenience and privacy [1] Industry Summary - Sildenafil, a selective inhibitor of phosphodiesterase type 5, is widely recognized for its effectiveness in treating erectile dysfunction [1] - The orally disintegrating tablet form, developed by Pfizer, was approved for importation into China in 2019, highlighting the growing demand for innovative drug delivery methods in the market [1]

股票代码：300016 股票简称：北陆药业 公告编号：2025-130 北京北陆药业股份有限公司 关于获得枸橼酸西地那非口崩片《药品注册证书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 近日，北京北陆药业股份有限公司（以下简称"公司"）收到国家药品监 督管理局核准签发的枸橼酸西地那非口崩片的《药品注册证书》。现将相关情 况公告如下： 一、药品的基本情况 药品通用名称：枸橼酸西地那非口崩片 主要成份：枸橼酸西地那非 剂型：片剂 上市许可持有人地址：北京市密云区水源西路 3 号 1 生产企业名称：北京北陆药业股份有限公司 生产企业地址：北京市密云区水源西路 3 号 规格：50mg（按 C₂₂H₃₀N₆O₄S 计） 注册分类：化学药品 4 类 药品有效期：24 个月 包装规格：1 片/板，1 板/盒；2 片/板，1 板/盒；4 片/板，1 板/盒；8 片/ 板，1 板/盒 处方药/非处方药：处方药 上市许可持有人名称：北京北陆药业股份有限公司 受理号：CYHS2402758 证书编号：2025S03924 药品注册标准编号：YBH32422025 药品批 ...

证券日报网讯 12月23日，北陆药业发布公告称，公司将于2026年1月8日召开2026年第一次临时股东 会。 （文章来源：证券日报） ...

证券日报网讯12月23日，北陆药业（300016）发布公告称，公司及公司控股子公司、全资子公司无违规 担保和逾期担保的情形，且不涉及诉讼的对外担保及因担保被判决败诉而应承担损失的情形。 ...

证券日报网讯 12月23日，北陆药业发布公告称，公司第九届董事会第七次会议审议通过《关于公司 2025年度以简易程序向特定对象发行股票方案（修订稿）的议案》等多项议案。 （文章来源：证券日报） ...

北京北陆药业股份有限公司 前次募集资金使用情况 北京北陆药业股份有限公司全体股东： 我们审核了后附的北京北陆药业股份有限公司（以下简称 北陆药业公司） 截至 2025 年 9 月 30 日的前次募集资金使用情况报告、前次募集资金使用情 况对照表和前次募集资金投资项目实现效益情况对照表。按照中国证监会 《监管规则适用指引——发行类第 7 号》的规定编制上述前次募集资金使用 情况报告及对照表是北陆药业公司董事会的责任，我们的责任是在实施鉴证 程序的基础上对北陆药业公司董事会编制的上述前次募集资金使用情况报告 及对照表提出鉴证结论。 我们按照《中国注册会计师其他鉴证业务准则第 3101 号——历史财务 信息审计或审阅以外的鉴证业务》的规定计划和实施鉴证工作，以合理确信 上述前次募集资金使用情况报告及对照表不存在重大错报。在鉴证工作中， 我们结合北陆药业公司实际情况，实施了包括核查会计记录等我们认为必要 的程序。我们相信，我们的鉴证工作为提出鉴证结论提供了合理的基础。 鉴证报告 致同会计师事务所（特殊普通合伙） 目 录 | 前次募集资金使用情况鉴证报告 | 1-2 | | --- | --- | | 公司前次募集资金 ...